The Global Cancer Gene Therapy Market Size was valued at USD 3.4 Billion in 2023 and is anticipated to reach USD 16.9 Billion by 2032 with a CAGR of 19.7% from 2024 to 2032.

Cancer gene therapy involves transferring nucleic acids into tumor or normal cells to eradicate or reduce tumor burden by cell-killing, immunomodulation, or correcting genetic mistakes to reverse the malignant state. Genes can be integrated into normal tissues to improve resistance to traditional cancer therapies. DNA may be injected into target cells both ex vivo and in vivo. Vectors help deliver genes to recipient cells. Vectors include replication-defective viruses, liposomes, and nucleic acid delivery complexes coupled with ligands. Viruses or non-viral vectors can transfer genes into cells. Gene therapy seeks to manage a cancer's changed genes or genetic alterations in order to limit its proliferation. Somatic gene therapy is an approach to cancer treatment that uses our own cells and DNA. This sort of gene therapy does not affect germ-line cells in the reproductive system, thus no genetic modifications may be handed down to other family members.

Somatic gene therapy is classified into four types: gene editing, replacement, addition, and inhibition.

Cancer Gene Therapy Market Dynamics

The global increase in cancer incidence is paving the way for the expansion of the cancer gene therapy industry. Rising desire for innovative cancer treatments, advances in genetic engineering, and significant investment in the discovery of new cancer medicines are expected to be important drivers of cancer gene therapy demand. Advances in gene technology, as well as expanding research into their applications in oncology, are driving firms to create innovative cancer gene treatments. Growing demand for tailored cancer therapies to reduce death rates, as well as supporting government financing to aid cancer patients, are projected to open up new prospects for cancer gene therapy providers in the future. However, high treatment costs, the possibility of adverse responses, and manufacturing hurdles are expected to limit the long-term growth potential of the cancer gene therapy industry.

Furthermore, favorable government laws for therapy are expected to increase the number of chances available in the Cancer Gene Therapy Market throughout the projected period. Furthermore, the danger of cancer gene therapy is reduced since a new gene inserted will integrate into the patient's genome and continue to operate without interfering with the operations of existing genes, which are essential elements predicting industry expansion in the next years. As a result, the reasons listed above contribute to an increase in the worldwide cancer gene therapy market share.

Market companies might seek to improve gene therapy capabilities through expansions, collaborations, joint ventures, acquisitions, and partnerships. This would contribute to the development of effective therapeutic medications for the treatment of various malignancies. GSK plc announced in April 2022 that it will acquire Sierra Oncology for £1.6 billion ($1.9 billion). This purchase would assist GSK plc improve its skills in the area of targeted treatments for treating uncommon kinds of cancer.

Global Cancer Gene Therapy Market Segment Analysis

Cancer Gene Therapy Market By Therapy

·       Gene Induced Immunotherapy

·       Oncolytic Virotherapy

·       Gene Transfer

According to the cancer gene therapy industry analysis, the gene-induced immunotherapy category is estimated to account for the bulk of the market share by 2023. This dominance is fueled by a rising emphasis on using the body's immune system to target and eradicate cancer cells, the development of improved CAR-T cell treatments, and more financing in this field. Gene-induced immunotherapy has demonstrated tremendous potential in treating several forms of cancer, contributing to its dominant position in the market.

Cancer Gene Therapy Market By End Use

·       Research Institutes

·       Biopharmaceutical Companies

·       Diagnostic Centers

·       Others

As per the cancer gene therapy market forecast, biopharmaceutical firms are predicted to have the largest market share in the Cancer Gene Therapy Market. This dominance is fueled by an increased emphasis on generating novel gene therapies for cancer therapy, significant investment in R&D, and the commercialization of advanced medicines. Biopharmaceutical firms are leading the way in turning gene therapy research into feasible clinical applications, aided by strategic collaborations, acquisitions, and a growing pipeline of medicines. Their vital role in bringing innovative cancer gene treatments to market maintains their dominance in the end-use category throughout this time.

Cancer Gene Therapy Market Regional Analysis

North America dominated the worldwide cancer gene therapy market in 2023, with a 40% market share, and is likely to continue to do so. Factors such as extensive expenditure in R&D, the existence of important competitors, and cooperation between biopharmaceutical firms, research institutes, and healthcare providers are propelling the North American market forward. Furthermore, government institutions such as the National Institutes of Health (NIH) in the United States provide significant funding for cancer research, which includes gene therapy. This funding goes toward fundamental research, translational studies, and clinical trials aimed at discovering and improving gene therapy techniques for various forms of cancer.

Asia-Pacific is expected to expand at a higher CARG throughout the projection period. The growing senior population might be one of the causes behind the expansion. Increased government investment and initiatives in healthcare, combined with technological improvements, help to drive sector growth.

Cancer Gene Therapy Market Leading Companies

The cancer gene therapy market players profiled in the report is Abeona Therapeutics Inc., Altor Bioscience Inc., Asklepios BioPharmaceutical Inc., BioCancell Inc., Bluebird bio Inc., Celgene Inc., Elevate Bio Inc., GenVec, Genelux Corporation, GSK plc., Introgen Therapeutics Inc., Merck KGaA, and OncoGenex Pharmaceuticals.

Cancer Gene Therapy Market Regions